{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:19:10Z","timestamp":1793215150443,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajpc.2025.101061","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T07:09:37Z","timestamp":1752822577000},"page":"101061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Sodium-glucose cotransporter 2 inhibitors and atherosclerosis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-9051","authenticated-orcid":false,"given":"Alexandr","family":"Ceasovschih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Balta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam Shams","family":"Aldeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Bianconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Barkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Ziya","family":"\u015eener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jakubov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Birhan","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren\u021biu","family":"\u0218orodoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victori\u021ba","family":"\u0218orodoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ajpc.2025.101061_bib0001","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","article-title":"Global trends in atherosclerotic cardiovascular disease","volume":"45","author":"Nedkoff","year":"2023","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101061_bib0002","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/1358863X221101653","article-title":"Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Patoulias","year":"2022","journal-title":"Vasc Med"},{"key":"10.1016\/j.ajpc.2025.101061_bib0003","doi-asserted-by":"crossref","unstructured":"Bor\u00e9n J., \u00d6\u00f6rni K., Catapano A.L. The link between diabetes and cardiovascular disease. 2024. p. 117607.","DOI":"10.1016\/j.atherosclerosis.2024.117607"},{"key":"10.1016\/j.ajpc.2025.101061_bib0004","unstructured":"Seferovic P.M., Coats A.J., Ponikowski P., Filippatos G., Huelsmann M., Jhund P.S., et al. European Society of Cardiology\/Heart FailureAssociation position paper on the role andsafety of new glucose-lowering drugs inpatients with heart failure. 2020."},{"issue":"12","key":"10.1016\/j.ajpc.2025.101061_bib0005","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 inhibitors: physiology and pharmacology","volume":"2","author":"Wright","year":"2021","journal-title":"Kidney360"},{"issue":"9","key":"10.1016\/j.ajpc.2025.101061_bib0006","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.7150\/thno.54498","article-title":"Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.ajpc.2025.101061_bib0007","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE\u2212\/\u2212 mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ajpc.2025.101061_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173040","article-title":"Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice","volume":"875","author":"Ganbaatar","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101061_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143396","article-title":"Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice","volume":"10","author":"Terasaki","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0010","article-title":"The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE\u2212\/\u2212 mice","volume":"2016","author":"Leng","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ajpc.2025.101061_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1149409","article-title":"Autophagy, innate immunity, and cardiac disease","volume":"11","author":"Santovito","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.ajpc.2025.101061_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116650","article-title":"Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose cotransporter 2 inhibitors: a systematic review","volume":"175","author":"Madonna","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101061_bib0013","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/cvr\/cvad009","article-title":"Empagliflozin inhibits excessive autophagy through the AMPK\/GSK3\u03b2 signalling pathway in diabetic cardiomyopathy","volume":"119","author":"Madonna","year":"2023","journal-title":"Cardiovas Res"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101061_bib0014","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE (-\/-) mice by activating autophagy and reducing ER stress and apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpc.2025.101061_bib0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-981-15-4272-5_18","article-title":"Autophagy, hyperlipidemia, and atherosclerosis","author":"Miao","year":"2020","journal-title":"Autophagy: Biology and Diseases: Clin Sci"},{"issue":"7","key":"10.1016\/j.ajpc.2025.101061_bib0016","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s43587-024-00642-y","article-title":"SGLT2 inhibition eliminates senescent cells and alleviates pathological aging","volume":"4","author":"Katsuumi","year":"2024","journal-title":"Nat aging"},{"issue":"21","key":"10.1016\/j.ajpc.2025.101061_bib0017","doi-asserted-by":"crossref","first-page":"12331","DOI":"10.1111\/jcmm.15699","article-title":"Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes","volume":"24","author":"Madonna","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ajpc.2025.101061_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-021-01252-3","article-title":"Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0019","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/jcm11010137","article-title":"Effects of SGLT2 inhibitors on atherosclerosis: lessons from cardiovascular clinical outcomes in type 2 diabetic patients and basic researches","volume":"11","author":"Xu","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101061_bib0020","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpc.2025.101061_bib0021","article-title":"Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice","volume":"18","author":"Takahashi","year":"2019","journal-title":"Biochem Biophys Rep"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101061_bib0022","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin suppresses hepcidin and increases erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.ajpc.2025.101061_bib0023","doi-asserted-by":"crossref","first-page":"9216","DOI":"10.3390\/ijms21239216","article-title":"Dapagliflozin does not modulate atherosclerosis in mice with insulin resistance","volume":"21","author":"Taberner-Cort\u00e9s","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpc.2025.101061_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2019.110487","article-title":"Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice","volume":"494","author":"Dimitriadis","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ajpc.2025.101061_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-021-01430-y","article-title":"Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity","volume":"20","author":"Liu","year":"2021","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ajpc.2025.101061_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0886-1","article-title":"Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice","volume":"18","author":"Mori","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ajpc.2025.101061_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174304","article-title":"Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK\/mTOR pathway","volume":"907","author":"Luo","year":"2021","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101061_bib0028","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/15384101.2022.2031429","article-title":"Dapagliflozin attenuates cholesterol overloading-induced injury in mice hepatocytes with type 2 diabetes mellitus (T2DM) via eliminating oxidative damages","volume":"21","author":"Yang","year":"2022","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ajpc.2025.101061_bib0029","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2018.02.028","article-title":"SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in ldlr\u2212\/\u2212 type 1 diabetic mice","volume":"271","author":"Al-Sharea","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2025.101061_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101061_bib0031","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s11357-022-00563-x","article-title":"SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice","volume":"44","author":"Soares","year":"2022","journal-title":"Geroscience"},{"key":"10.1016\/j.ajpc.2025.101061_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01066-9","article-title":"Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury","volume":"19","author":"Lahnwong","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ajpc.2025.101061_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116994","article-title":"SGLT2 inhibitor Dapagliflozin alleviates cardiac dysfunction and fibrosis after myocardial infarction by activating PXR and promoting angiogenesis","volume":"177","author":"Wang","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0034","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022761","article-title":"Sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin stabilizes diabetes-induced atherosclerotic plaque instability","volume":"11","author":"Chen","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","article-title":"SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart","volume":"4","author":"Lim","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101061_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22423","article-title":"Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats","volume":"9","author":"Zhong","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ajpc.2025.101061_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1255904","article-title":"Dapagliflozin promotes angiogenesis in hindlimb ischemia mice by inducing M2 macrophage polarization","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101061_bib0038","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41401-022-01031-0","article-title":"SGLT2 inhibitor empagliflozin promotes revascularization in diabetic mouse hindlimb ischemia by inhibiting ferroptosis","volume":"44","author":"J-x","year":"2023","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101061_bib0039","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1358863X20961153","article-title":"Canagliflozin impedes ischemic hind-limb recovery in the setting of diabetes","volume":"26","author":"Nalugo","year":"2021","journal-title":"Vasc Med"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12933-024-02174-6","article-title":"The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice","volume":"23","author":"Vercalsteren","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"21","key":"10.1016\/j.ajpc.2025.101061_bib0041","doi-asserted-by":"crossref","first-page":"6544","DOI":"10.3390\/jcm11216544","article-title":"Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu","volume":"11","author":"Yaribeygi","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101061_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100176","article-title":"The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic \u03b2-oxidation, and induces ketosis","volume":"63","author":"Wallenius","year":"2022","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101061_bib0043","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2304667","article-title":"The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis","volume":"55","author":"Stachteas","year":"2023","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101061_bib0044","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4070\/kcj.2020.0303","article-title":"Sodium\/glucose co-transporter 2 inhibitor, empagliflozin, alleviated transient expression of SGLT2 after myocardial infarction","volume":"51","author":"Lee","year":"2021","journal-title":"Korean Circ J"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101061_bib0045","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s13300-023-01454-w","article-title":"Treatment with SGLT2 inhibitors in patients with diabetes mellitus and extensive coronary artery disease: mortality and cardiovascular outcomes","volume":"14","author":"Chipayo-Gonzales","year":"2023","journal-title":"Diabetes Ther"},{"issue":"15","key":"10.1016\/j.ajpc.2025.101061_bib0046","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.ajpc.2025.101061_bib0047","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3390\/cells12182221","article-title":"Canagliflozin, an inhibitor of the Na+-coupled d-glucose cotransporter, SGLT2, inhibits astrocyte swelling and brain swelling in cerebral ischemia","volume":"12","author":"Shim","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101061_bib0048","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1530\/JOE-17-0263","article-title":"Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice","volume":"234","author":"Millar","year":"2017","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ajpc.2025.101061_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","volume":"394","author":"Bechmann","year":"2024","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-024-01572-0","article-title":"Impact of SGLT2 inhibitors on lipoproteins in type 2 diabetes","volume":"25","author":"Corral","year":"2025","journal-title":"Curr Diab Rep"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0051","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clinthera.2013.11.002","article-title":"Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study","volume":"36","author":"Ji","year":"2014","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101061_bib0052","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s40200-023-01305-2","article-title":"Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial","volume":"22","author":"Taheri","year":"2023","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0053","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13098-023-01074-1","article-title":"Beneficial effects of luseogliflozin on lipid profile and liver function in patients with type 2 diabetes mellitus (BLUE trial): a single-center, single-arm, open-label prospective study","volume":"15","author":"Hajika","year":"2023","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101061_bib0054","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.dsx.2019.01.016","article-title":"Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center","volume":"13","author":"Calapkulu","year":"2019","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0055","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/2431441","article-title":"The effect of Canagliflozin on high-density lipoprotein cholesterol and angiopoietin-like protein 3 in type 2 diabetes mellitus","volume":"2024","author":"Liu","year":"2024","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.ajpc.2025.101061_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.992327","article-title":"Does Dapagliflozin influence arterial stiffness and levels of circulating anti-aging hormone soluble Klotho in people with type 2 diabetes and kidney disease? Results of a randomized parallel group clinical trial","volume":"9","author":"Karalliedde","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101061_bib0057","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.medcle.2019.05.014","article-title":"Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus","volume":"154","author":"Santiago","year":"2020","journal-title":"Med Clin (English Edition)"},{"key":"10.1016\/j.ajpc.2025.101061_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101061_bib0059","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ajpc.2025.101061_bib0060","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajpc.2025.101061_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0839-8","article-title":"How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial","volume":"18","author":"Bosch","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"10.1016\/j.ajpc.2025.101061_bib0062","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jch.13988","article-title":"Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: the multicenter, exploratory LUSCAR study","volume":"22","author":"Kario","year":"2020","journal-title":"J Clin Hypertens"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101061_bib0063","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajpc.2025.101061_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ajpc.2025.101061_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01206-1","article-title":"Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial","volume":"20","author":"Katakami","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"Supplement_2","key":"10.1016\/j.ajpc.2025.101061_bib0066","doi-asserted-by":"crossref","first-page":"ehad655","DOI":"10.1093\/eurheartj\/ehad655.2567","article-title":"Effect of sodium-glucose co-transporter inhibitors on arterial stiffness in patients with type 2 diabetes mellitus","volume":"44","author":"Szigeti","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101061_bib0067","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101061_bib0068","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ajpc.2025.101061_bib0069","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ajpc.2025.101061_bib0070","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101061_bib0071","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The Dapagliflozin and Prevention of adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.ajpc.2025.101061_bib0072","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0073","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12933-022-01627-0","article-title":"Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention","volume":"21","author":"Zhu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101061_bib0074","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/bcp.13903","article-title":"Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease: a randomised study","volume":"85","author":"Phrommintikul","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"21","key":"10.1016\/j.ajpc.2025.101061_bib0075","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ajpc.2025.101061_bib0076","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2025.101061_bib0077","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"10365","key":"10.1016\/j.ajpc.2025.101061_bib0078","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Herrington","year":"2022","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ajpc.2025.101061_bib0079","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ajpc.2025.101061_bib0080","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajpc.2025.101061_bib0081","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/ejhf.2064","article-title":"Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-preserved trial","volume":"22","author":"Anker","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101061_bib0082","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat med"},{"key":"10.1016\/j.ajpc.2025.101061_bib0083","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40119-020-00208-0","article-title":"The effect of empagliflozin on platelet function profiles in patients with stable coronary artery disease in Trinidad: the EFFECT pilot study","volume":"10","author":"Seecheran","year":"2021","journal-title":"Cardiol Ther"},{"issue":"41","key":"10.1016\/j.ajpc.2025.101061_bib0084","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0085","doi-asserted-by":"crossref","DOI":"10.1002\/clc.24158","article-title":"Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double-blind placebo-controlled trial (EMPT-ANGINA Trial)","volume":"47","author":"Mansouri","year":"2024","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ajpc.2025.101061_bib0086","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/s00380-020-01621-0","article-title":"Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes","volume":"35","author":"Hashikata","year":"2020","journal-title":"Heart Vessels"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101061_bib0087","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ajpc.2025.101061_bib0088","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"10.1016\/j.ajpc.2025.101061_bib0089","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2025.101061_bib0090","doi-asserted-by":"crossref","first-page":"E898","DOI":"10.59958\/hsf.7627","article-title":"Efficacy and safety of Canagliflozin in STEMI patients with type 2 diabetes after PCI: a retrospective study","author":"Chen","year":"2024","journal-title":"Heart Surg Forum"},{"issue":"15","key":"10.1016\/j.ajpc.2025.101061_bib0091","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101061_bib0092","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ajpc.2025.101061_bib0093","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ajpc.2025.101061_bib0094","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3390\/ph17091127","article-title":"The influence of Dapagliflozin on foot microcirculation in patients with type 2 diabetes with and without peripheral arterial disease\u2014a pilot study","volume":"17","author":"Bradari\u0107","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"18","key":"10.1016\/j.ajpc.2025.101061_bib0095","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","article-title":"The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study","volume":"42","author":"Paul","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101061_bib0096","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/dom.14671","article-title":"Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial","volume":"24","author":"Barraclough","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101061_bib0097","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.14593","article-title":"Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study","volume":"24","author":"Patorno","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101061_bib0098","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/STROKEAHA.116.015756","article-title":"Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk","volume":"48","author":"Zinman","year":"2017","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101061_bib0099","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dom.13077","article-title":"Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study","volume":"20","author":"Persson","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajpc.2025.101061_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0919-9","article-title":"Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101061_bib0101","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/STROKEAHA.118.023009","article-title":"Canagliflozin and stroke in type 2 diabetes mellitus: results from the randomized CANVAS program trials","volume":"50","author":"Zhou","year":"2019","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101061_bib0102","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/STROKEAHA.120.031623","article-title":"Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis","volume":"52","author":"Zhou","year":"2021","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.ajpc.2025.101061_bib0103","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups: results from the randomized CREDENCE trial","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101061_bib0104","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/pds.4985","article-title":"Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Li","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101061_bib0105","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.5114\/aoms\/141941","article-title":"PoLA\/CFPiP\/PCS\/PSLD\/PSD\/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021","volume":"17","author":"Banach","year":"2021","journal-title":"Arch Med Sci"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101061_bib0106","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/HJH.0000000000002690","article-title":"Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"39","author":"Papadopoulou","year":"2021","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101061_bib0107","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7570\/jomes20040","article-title":"Effects of 6 months of dapagliflozin treatment on metabolic profile and endothelial cell dysfunction for obese type 2 diabetes mellitus patients without atherosclerotic cardiovascular disease","volume":"29","author":"Hong","year":"2020","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.ajpc.2025.101061_bib0108","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.826604","article-title":"Effects of SGLT-2 inhibitors on vascular endothelial function and arterial stiffness in subjects with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Wei","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ajpc.2025.101061_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108781","article-title":"The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: a meta-analysis of randomized controlled trials","author":"Rizos","year":"2024","journal-title":"J Diabetes Complic"},{"issue":"22","key":"10.1016\/j.ajpc.2025.101061_bib0110","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ajpc.2025.101061_bib0111","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction: subanalysis from the DECLARE-TIMI 58 trial","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2025.101061_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT Registry","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.ajpc.2025.101061_bib0113","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Group","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2025.101061_bib0114","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.777083","article-title":"Effects of sodium-glucose transporter 2 inhibitors (SGLT2-I) in patients with ischemic heart disease (IHD) treated by coronary artery bypass grafting via MiECC: inflammatory burden, and clinical outcomes at 5 years of follow-up","volume":"12","author":"Sardu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0115","doi-asserted-by":"crossref","DOI":"10.37358\/RC.18.1.6084","article-title":"Is there a sex difference of cardiovascular risk factors in patients with acute myocardial infarction","volume":"69","author":"Anghel","year":"2018","journal-title":"Rev Chim"},{"issue":"10166","key":"10.1016\/j.ajpc.2025.101061_bib0116","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"10354","key":"10.1016\/j.ajpc.2025.101061_bib0117","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101061_bib0118","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/ehjcvp\/pvaa051","article-title":"The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management","volume":"6","author":"Sabouret","year":"2020","journal-title":"Cardiovasc. Pharmacother."},{"issue":"36","key":"10.1016\/j.ajpc.2025.101061_bib0119","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.ajpc.2025.101061_bib0120","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Members","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.ajpc.2025.101061_bib0121","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Diseases GBoC, Collaborators R. Global burden of cardiovascular diseases and risks, 1990-2022","volume":"82","author":"Mensah","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.ajpc.2025.101061_bib0122","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.3390\/ijerph19169801","article-title":"Approaches to peripheral artery disease in diabetes: are there any differences?","volume":"19","author":"Achim","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"10.1016\/j.ajpc.2025.101061_bib0123","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/ATVBAHA.123.319156","article-title":"Presence of peripheral artery disease is associated with increased risk of heart failure events: insights from EMPEROR-Pooled","volume":"43","author":"Verma","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0124","doi-asserted-by":"crossref","DOI":"10.34172\/jpe.2025.38251","article-title":"Limb amputation following sodium-glucose cotransporter type 2 inhibitor therapy","volume":"10","author":"Alipour","year":"2025","journal-title":"J Prev Epidemiol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101061_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234065","article-title":"Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis","volume":"15","author":"Heyward","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ajpc.2025.101061_bib0126","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajpc.2025.101061_bib0127","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.hfc.2022.03.001","article-title":"SGLT2 inhibitors and peripheral vascular events: a review of the literature","volume":"18","author":"Marchiori","year":"2022","journal-title":"Heart Fail Clin"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0128","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1358863X221143811","article-title":"Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: a review","volume":"28","author":"Skeik","year":"2023","journal-title":"Vasc Med"},{"issue":"24","key":"10.1016\/j.ajpc.2025.101061_bib0129","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/eurheartj\/ehad276","article-title":"Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER","volume":"44","author":"Butt","year":"2023","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101061_bib0130","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.101061_bib0131","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1253\/circj.CJ-17-0040","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and stroke","volume":"81","author":"Kimura","year":"2017","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.ajpc.2025.101061_bib0132","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94945-4","article-title":"Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Tsai","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpc.2025.101061_bib0133","article-title":"SGLT-2 inhibitors reduce the risk of cerebrovascular\/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies","volume":"172","author":"Mascolo","year":"2021","journal-title":"Pharmacol Res"},{"issue":"8","key":"10.1016\/j.ajpc.2025.101061_bib0134","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.3390\/jcm12082814","article-title":"Cerebrovascular, cognitive and cardiac benefits of SGLT2 inhibitors therapy in patients with atrial fibrillation and type 2 diabetes mellitus: results from a global federated health network analysis","volume":"12","author":"Proietti","year":"2023","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.ajpc.2025.101061_bib0135","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027764","article-title":"Sodium-glucose cotransporter-2 inhibitor prevents stroke in patients with diabetes and atrial fibrillation","volume":"12","author":"Chang","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101061_bib0136","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105708","article-title":"Sodium-glucose cotransporter-2 inhibitors and protection against stroke in patients with type 2 diabetes and impaired renal function: a systematic review and meta-analysis","volume":"30","author":"Barkas","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.ajpc.2025.101061_bib0137","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(24)00362-0","article-title":"Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial","author":"Aggarwal","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.ajpc.2025.101061_bib0138","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1038\/s41401-021-00835-w","article-title":"Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review","volume":"43","author":"Zhang","year":"2022","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"10.1016\/j.ajpc.2025.101061_bib0139","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1111\/bcp.15711","article-title":"Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: a disproportionality analysis","volume":"89","author":"Gravel","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.ajpc.2025.101061_bib0140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/L20-0549","article-title":"Rosuvastatin myotoxicity after starting canagliflozin treatment: a case report","volume":"173","author":"Brailovski","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajpc.2025.101061_bib0141","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.670155","article-title":"Platelet effects of anti-diabetic therapies: new perspectives in the management of patients with diabetes and cardiovascular disease","volume":"12","author":"Nusca","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajpc.2025.101061_bib0142","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40262-013-0128-8","article-title":"Drug\u2013drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ajpc.2025.101061_bib0143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11906-021-01131-y","article-title":"Drug interactions with antihypertensives","volume":"23","author":"Fravel","year":"2021","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"10.1016\/j.ajpc.2025.101061_bib0144","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.ajpc.2025.101061_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108827","article-title":"Association of sodium glucose co-transporter-2 inhibitors with risk of diabetic ketoacidosis among hospitalized patients: a multicentre cohort study","volume":"38","author":"Sarma","year":"2024","journal-title":"J Diabetes Complications"},{"issue":"11","key":"10.1016\/j.ajpc.2025.101061_bib0146","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium\u2013glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10296","key":"10.1016\/j.ajpc.2025.101061_bib0147","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ajpc.2025.101061_bib0148","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.867","article-title":"Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions","volume":"9","author":"Matharu","year":"2021","journal-title":"Pharmacol Res Perspect"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725001369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725001369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:58:49Z","timestamp":1760648329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667725001369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":148,"alternative-id":["S2666667725001369"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101061","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose cotransporter 2 inhibitors and atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.101061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101061"}}